Looking back over 2023 and welcome to the 21^st issue of Personalized Medicine

References

• 1. Bhandari NR, Hess LM, Parikh RC. Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA. Pers. Med. 20(2), 131–142 (2023).
  CASGoogle Scholar
• 2. Rutten-van Mölken M, Versteegh M, Nagy B, Wordsworth S. HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead. Pers. Med. 20(4), 299–303 (2023).
  Google Scholar
• 3. Koleva-Kolarova R, Vellekoop H, Huygens S et al. Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Pers. Med. 20(4), 357–374 (2023).
  CASGoogle Scholar
• 4. Koleva-Kolarova R, Vellekoop H, Huygens S et al. Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK. Pers. Med. 20(4), 339–355 (2023).
  CASGoogle Scholar
• 5. Koleva-Kolarova R, Szilberhorn L, Zelei T et al. Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Pers. Med. 20(4), 305–319 (2023).
  CASGoogle Scholar
• 6. Kovács G, Nagy D, Szilberhorn L et al. Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young. Pers. Med. 20(4), 375–385 (2023).
  CASGoogle Scholar
• 7. Shimada R, Alden EN, Hoff K et al. SARS-CoV-2 variant identification using a genome tiling array and genotyping probes. Pers. Med. 20(1), 13–25 (2023).
  CASGoogle Scholar
• 8. Abdi E, Latifi-Navid S. Long noncoding RNA polymorphisms and hepatocellular carcinoma and pancreatic cancer risk. Pers. Med. 20(2), 193–200 (2023).
  CASGoogle Scholar
• 9. Aguiar PN, Matsas S, Dienstmann R, Ferreira CG. Challenges and opportunities in building a health economic framework for personalized medicine in oncology. Pers. Med. 20(5), 453–460 (2023).
  CASGoogle Scholar